Bianca Cioni1, Ekaterina S Jordanova2, Erik Hooijberg3, Rianne van der Linden3, Renee X de Menezes4, Katherine Tan5, Stefan Willems3, Joris B W Elbers6,7, Annegien Broeks8, Andries M Bergman1,5, Charlotte L Zuur6, Jan Paul de Boer5. 1. Division of Oncogenomics, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 2. Center for Gynecologic Oncology, VU University Medical Center, Amsterdam, The Netherlands. 3. Division of Pathology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Division of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands. 5. Division of Medical Oncology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. Division of Head and Neck Surgery, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 7. Division of Radiation Oncology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 8. Core Facility Molecular Pathology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV-positive OPSCC patient. METHODS: A comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD-L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients. RESULTS: We found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor-associated macrophages (TAMs). High HLA-DP/DQ/DR expression and low number of TAMs were associated with longer disease-specific survival and disease-free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis. CONCLUSIONS: \We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy.
BACKGROUND:Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV-positive OPSCC patient. METHODS: A comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD-L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients. RESULTS: We found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor-associated macrophages (TAMs). High HLA-DP/DQ/DR expression and low number of TAMs were associated with longer disease-specific survival and disease-free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis. CONCLUSIONS: \We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy.
Authors: H S van Monsjou; M L F van Velthuysen; M W M van den Brekel; E S Jordanova; C J M Melief; A J M Balm Journal: Int J Cancer Date: 2011-08-02 Impact factor: 7.396
Authors: Brian Ruffell; Debbie Chang-Strachan; Vivien Chan; Alexander Rosenbusch; Christine M T Ho; Nancy Pryer; Dylan Daniel; E Shelley Hwang; Hope S Rugo; Lisa M Coussens Journal: Cancer Cell Date: 2014-10-16 Impact factor: 31.743
Authors: Jérôme Galon; Franck Pagès; Francesco M Marincola; Helen K Angell; Magdalena Thurin; Alessandro Lugli; Inti Zlobec; Anne Berger; Carlo Bifulco; Gerardo Botti; Fabiana Tatangelo; Cedrik M Britten; Sebastian Kreiter; Lotfi Chouchane; Paolo Delrio; Hartmann Arndt; Martin Asslaber; Michele Maio; Giuseppe V Masucci; Martin Mihm; Fernando Vidal-Vanaclocha; James P Allison; Sacha Gnjatic; Leif Hakansson; Christoph Huber; Harpreet Singh-Jasuja; Christian Ottensmeier; Heinz Zwierzina; Luigi Laghi; Fabio Grizzi; Pamela S Ohashi; Patricia A Shaw; Blaise A Clarke; Bradly G Wouters; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Ena Wang; Jill O'Donnell-Tormey; Christine Lagorce; Graham Pawelec; Michael I Nishimura; Robert Hawkins; Réjean Lapointe; Andreas Lundqvist; Samir N Khleif; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Richard Palmqvist; Iris D Nagtegaal; Yili Wang; Corrado D'Arrigo; Scott Kopetz; Frank A Sinicrope; Giorgio Trinchieri; Thomas F Gajewski; Paolo A Ascierto; Bernard A Fox Journal: J Transl Med Date: 2012-10-03 Impact factor: 5.531
Authors: Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce Journal: Nat Med Date: 2013-09-22 Impact factor: 53.440
Authors: Simone Punt; Emilie A C Dronkers; Marij J P Welters; Renske Goedemans; Senada Koljenović; Elisabeth Bloemena; Peter J F Snijders; Arko Gorter; Sjoerd H van der Burg; Robert J Baatenburg de Jong; Ekaterina S Jordanova Journal: Cancer Immunol Immunother Date: 2016-02-22 Impact factor: 6.968
Authors: Kenneth Oguejiofor; Henry Galletta-Williams; Simon J Dovedi; Darren L Roberts; Peter L Stern; Catharine M L West Journal: Oncotarget Date: 2017-02-28
Authors: Astrid De Meulenaere; Tijl Vermassen; Sandrine Aspeslagh; Philippe Deron; Fréderic Duprez; Debby Laukens; Jo Van Dorpe; Liesbeth Ferdinande; Sylvie Rottey Journal: Oncotarget Date: 2017-07-06
Authors: Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer Journal: Head Neck Date: 2018-12-14 Impact factor: 3.147
Authors: Steven F Gameiro; Farhad Ghasemi; John W Barrett; Anthony C Nichols; Joe S Mymryk Journal: Cancers (Basel) Date: 2019-08-07 Impact factor: 6.639
Authors: Joris L Vos; Joris B W Elbers; Oscar Krijgsman; Joleen J H Traets; Xiaohang Qiao; Anne M van der Leun; Yoni Lubeck; Iris M Seignette; Laura A Smit; Stefan M Willems; Michiel W M van den Brekel; Richard Dirven; M Baris Karakullukcu; Luc Karssemakers; W Martin C Klop; Peter J F M Lohuis; Willem H Schreuder; Ludi E Smeele; Lilly-Ann van der Velden; I Bing Tan; Suzanne Onderwater; Bas Jasperse; Wouter V Vogel; Abrahim Al-Mamgani; Astrid Keijser; Vincent van der Noort; Annegien Broeks; Erik Hooijberg; Daniel S Peeper; Ton N Schumacher; Christian U Blank; Jan Paul de Boer; John B A G Haanen; Charlotte L Zuur Journal: Nat Commun Date: 2021-12-22 Impact factor: 14.919
Authors: Saskia J Santegoets; Chantal L Duurland; Ekaterina J Jordanova; Vanessa J van Ham; Ilina Ehsan; Nikki M Loof; Vipin Narang; Charles A Dutertre; Florent Ginhoux; Sylvia L van Egmond; Marij J P Welters; Sjoerd H van der Burg Journal: J Immunother Cancer Date: 2020-08 Impact factor: 13.751
Authors: Barbara Seliger; Chiara Massa; Bo Yang; Daniel Bethmann; Matthias Kappler; Alexander Walter Eckert; Claudia Wickenhauser Journal: Int J Mol Sci Date: 2020-09-24 Impact factor: 5.923
Authors: Anders Näsman; Stefan Holzhauser; Ourania N Kostopoulou; Mark Zupancic; Andreas Ährlund-Richter; Juan Du; Tina Dalianis Journal: Viruses Date: 2021-05-14 Impact factor: 5.048